DLA Piper represented Galaxy Biotech, LLC, in its licensing to Roche of exclusive worldwide development and commercialization rights of its antibodies targeting fibroblast growth factor 2 (FGF2) for the treatment of cancer.

Under the terms of the agreement, Galaxy will receive a US$8 million license fee, and milestone payments contingent on various preclinical, clinical and regulatory developments events, as well as royalties on product sales.

FGF2 is overexpressed in many types of cancer, and for some tumor types a high level of FGF2 expression correlates with poor clinical outcome. FGF2 has been shown to stimulate not only angiogenesis but also lymphangiogenesis, which may be important in cancer metastasis. Galaxy has developed a novel antibody that neutralizes the biological activity of FGF2, and in published scientific work has shown that the antibody effectively inhibits the growth of certain tumors in animal models.

The team representing Galaxy was led by DLA Piper’s Tom Duley (San Francisco). Geller Biopharm Inc served as Galaxy’s exclusive agent for this license agreement.



Related Posts:

Leave a Reply